FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079720175> ?p ?o ?g. }

• W2079720175 endingPage "1124" @default.
• W2079720175 startingPage "1115" @default.
• W2079720175 abstract "Abstract BACKGROUND. Although aggressive dose escalation strategies were designed to improve the risk‐benefit profile of phase 1 oncology trials, they have not been adequately studied. The prevalence of several novel trial designs and their association with a variety of clinical endpoints was evaluated. METHODS. A review of the literature was performed to identify phase 1 oncology studies of cytotoxic agents published from 2002 through 2004. RESULTS. Of 955 phase 1 oncology articles initially identified, 149 studies, comprising 4532 patients, were analyzed. Only 34% of studies utilized aggressive dose escalation schemes, 22% permitted intrapatient dose escalation, and only 28% enrolled fewer than 3 patients to any dose level. Studies that allowed intrapatient dose escalation or used fewer than 3 patients per dose were not associated with different rates of response or toxicity, nor did they increase the number of patients who received the recommended phase 2 dose. However, aggressive dose escalations were associated with increased rates of both hematologic (17% vs 10%) and nonhematologic (17% vs 13%) toxicity with similar response rates. Only studies that used conservative dose escalation designs and those that studied U.S. Food and Drug Administration (FDA)‐approved agents required fewer patients to complete a trial. Trials of FDA‐approved agents were also associated with higher response rates than trials of non‐FDA‐approved agents (10% vs 2%), without an increased risk of toxicity. CONCLUSIONS. Several novel aggressive design strategies intended to improve the risk‐benefit profile of phase 1 oncology trials are not associated with improved clinical outcome, and may be harmful in certain instances. Cancer 2007. Published 2007 American Cancer Society." @default.
• W2079720175 created "2016-06-24" @default.
• W2079720175 creator A5011045210 @default.
• W2079720175 creator A5011221111 @default.
• W2079720175 creator A5012567636 @default.
• W2079720175 creator A5029296725 @default.
• W2079720175 creator A5063313676 @default.
• W2079720175 creator A5078289544 @default.
• W2079720175 creator A5083533154 @default.
• W2079720175 date "2007-08-20" @default.
• W2079720175 modified "2023-10-17" @default.
• W2079720175 title "Risks and benefits associated with novel phase 1 oncology trial designs" @default.
• W2079720175 cites W1787102412 @default.
• W2079720175 cites W1923650832 @default.
• W2079720175 cites W1933724083 @default.
• W2079720175 cites W1964708144 @default.
• W2079720175 cites W1989497622 @default.
• W2079720175 cites W1990807227 @default.
• W2079720175 cites W1992346046 @default.
• W2079720175 cites W1995689784 @default.
• W2079720175 cites W2005634164 @default.
• W2079720175 cites W2012800796 @default.
• W2079720175 cites W2020352568 @default.
• W2079720175 cites W2023021949 @default.
• W2079720175 cites W2038725811 @default.
• W2079720175 cites W2062816023 @default.
• W2079720175 cites W2071607258 @default.
• W2079720175 cites W2076108528 @default.
• W2079720175 cites W2080675410 @default.
• W2079720175 cites W2091787103 @default.
• W2079720175 cites W2107427969 @default.
• W2079720175 cites W2119597015 @default.
• W2079720175 cites W2126551611 @default.
• W2079720175 cites W2128373232 @default.
• W2079720175 cites W2129546350 @default.
• W2079720175 cites W2130344873 @default.
• W2079720175 cites W2140081776 @default.
• W2079720175 cites W2141086589 @default.
• W2079720175 cites W2142613706 @default.
• W2079720175 cites W2148666312 @default.
• W2079720175 cites W2149073952 @default.
• W2079720175 cites W2149626936 @default.
• W2079720175 cites W2165524738 @default.
• W2079720175 cites W2315885933 @default.
• W2079720175 cites W2325726156 @default.
• W2079720175 cites W2414369265 @default.
• W2079720175 cites W37050328 @default.
• W2079720175 doi "https://doi.org/10.1002/cncr.22878" @default.
• W2079720175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17628485" @default.
• W2079720175 hasPublicationYear "2007" @default.
• W2079720175 type Work @default.
• W2079720175 sameAs 2079720175 @default.
• W2079720175 citedByCount "35" @default.
• W2079720175 countsByYear W20797201752012 @default.
• W2079720175 countsByYear W20797201752013 @default.
• W2079720175 countsByYear W20797201752014 @default.
• W2079720175 countsByYear W20797201752016 @default.
• W2079720175 countsByYear W20797201752018 @default.
• W2079720175 countsByYear W20797201752019 @default.
• W2079720175 countsByYear W20797201752020 @default.
• W2079720175 countsByYear W20797201752022 @default.
• W2079720175 crossrefType "journal-article" @default.
• W2079720175 hasAuthorship W2079720175A5011045210 @default.
• W2079720175 hasAuthorship W2079720175A5011221111 @default.
• W2079720175 hasAuthorship W2079720175A5012567636 @default.
• W2079720175 hasAuthorship W2079720175A5029296725 @default.
• W2079720175 hasAuthorship W2079720175A5063313676 @default.
• W2079720175 hasAuthorship W2079720175A5078289544 @default.
• W2079720175 hasAuthorship W2079720175A5083533154 @default.
• W2079720175 hasBestOaLocation W20797201751 @default.
• W2079720175 hasConcept C126322002 @default.
• W2079720175 hasConcept C143998085 @default.
• W2079720175 hasConcept C2777334693 @default.
• W2079720175 hasConcept C29730261 @default.
• W2079720175 hasConcept C31760486 @default.
• W2079720175 hasConcept C535046627 @default.
• W2079720175 hasConcept C71924100 @default.
• W2079720175 hasConceptScore W2079720175C126322002 @default.
• W2079720175 hasConceptScore W2079720175C143998085 @default.
• W2079720175 hasConceptScore W2079720175C2777334693 @default.
• W2079720175 hasConceptScore W2079720175C29730261 @default.
• W2079720175 hasConceptScore W2079720175C31760486 @default.
• W2079720175 hasConceptScore W2079720175C535046627 @default.
• W2079720175 hasConceptScore W2079720175C71924100 @default.
• W2079720175 hasIssue "5" @default.
• W2079720175 hasLocation W20797201751 @default.
• W2079720175 hasLocation W20797201752 @default.
• W2079720175 hasOpenAccess W2079720175 @default.
• W2079720175 hasPrimaryLocation W20797201751 @default.
• W2079720175 hasRelatedWork W2088620963 @default.
• W2079720175 hasRelatedWork W2170271130 @default.
• W2079720175 hasRelatedWork W2366254154 @default.
• W2079720175 hasRelatedWork W2402743643 @default.
• W2079720175 hasRelatedWork W2528167051 @default.
• W2079720175 hasRelatedWork W2920891938 @default.
• W2079720175 hasRelatedWork W4244546467 @default.
• W2079720175 hasRelatedWork W4312693609 @default.
• W2079720175 hasRelatedWork W4313063054 @default.

• next